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1. Introduction 
Sarcoidosis was first described by a British dermatologist, Jonathan Hutchison in 1869.  
Since then it has been seen in almost every part of the world and continues to engender 
considerable interest and concern amongst scientists and medical providers alike because 1) 
the cause is unknown, 2) it may involve any organ system in the body, 3) the course and 
prognosis vary from spontaneous resolution to progressive disability and death, and 4) 
there is no truly satisfactory treatment. Just as there are many unknowns about the illness in 
general, its diagnosis remains problematic despite extensive study and voluminous 
reporting in the scientific literature. Our objective in this chapter is to provide an overview 
of current knowledge on the diagnostic approach in sarcoidosis.  
2. Definition 
Sarcoidosis is a granulomatous disease of unknown etiology with protean manifestations 
that affects people throughout the world (1).  
3. Diagnostic criteria 
In many respects, sarcoidosis is a diagnosis of exclusion. Although it has been asserted that 
the method of diagnosis has been established (1), a more recent expert view is that the 
diagnosis is never completely secure (2).  There is no single diagnostic test. It is often 
suspected when a chest radiograph performed for non-specific symptoms such as dyspnea 
or chest pain shows the characteristic findings of bilateral hilar adenopathy with or without 
diffuse lung infiltrates.  In other cases, especially when thoracic manifestations are atypical 
or absent, the diagnosis remains obscure. Thus, the diagnostic approach may be straight 
forward, but in some situations will be complex and involve multiple diagnostic modalities.  
The diagnosis of sarcoidosis is based on the following criteria: 1) a compatible clinical 
and/or radiographic picture 2) histological evidence of non-caseating granulomas and 3) 
exclusion of other conditions with similar histology. An algorithm for approaching the 
diagnosis which reflects currently available data is shown in figure 1. The diagnostic 
evaluation should also evaluate the extent and severity of organ involvement, and assess 
disease stability and the need for treatment with corticosteroids (1).  
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Fig. 1. An approach to the diagnosis of sarcoidosis* 
4. Initial evaluation 
Key data from the medical history, physical findings, and routine laboratory and 
radiographic studies figure prominently in the diagnostic approach to sarcoidosis.  
Nonspecific constitutional manifestations such as fever, fatigue, malaise, and weight loss 
occur in up to one third of patients with sarcoidosis (3). Sarcoidosis can involve virtually 
every organ system and the review of systems can provide important diagnostic clues.  
Factors associated with a higher clinical likelihood of sarcoidosis include African American 
or Northern European descent, nonsmokers, and a family history of sarcoidosis (4-7). A 
detailed occupational history should include prior exposure to beryllium, risk factors for 
hypersensitivity pneumonitis, and exposure to tuberculosis or fungal pathogens all of which 
can mimic sarcoidosis (1).  
The physical examination should be performed with similar attention to detail.  Respiratory 
findings may include wheezing or rales. Frequently encountered extra-thoracic 
manifestations include peripheral lymphadenopathy, liver or splenic enlargement, ocular 
involvement, parotitis, facial nerve palsy, and a variety of cutaneous lesions including direct 
involvement by sarcoidosis and non-specific lesions especially erythema  nodosum (8).  
Initial laboratory studies should include a complete blood count and comprehensive 
metabolic panel with particular attention to liver function and calcium levels. A tuberculin 
skin test and (where appropriate) fungal skin tests and serologies should be done. A variety 
                                                 
* Reprinted with permission. Judson MA. The diagnosis of sarcoidosis. Clinics in Chest Medicine 2008; 
29:415-427. Copyright Elsevier. 
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of electrocardiographic abnormailities may indicate cardiac sarcoidosis including 
conduction defects, atrial and ventricular extrasystoles and arryhythmias. Pulmonary 
function tests are crucial for quantification of pulmonary impairment, and to provide a 
baseline for assessment of future stability or progression. Restrictive and/or obstructive 
ventilatory defects and diffusion impairment are common. 
Compatible radiographic imaging is one of the diagnostic criteria for sarcoidosis.  The most 
common abnormalities on plain chest radiographs are bilateral, symmetric hilar adenopathy 
with or without lung infiltrates.  The classification system developed by Scadding 50 years ago 
remains in use today (9). In stage I hilar and mediastinal lymphadenopathy alone are present. 
Stage II is defined by adenopathy plus pulmonary infiltrates, stage III by pulmonary infiltrates 
alone and stage IV includes radiographic evidence of pulmonary fibrosis (Figs. 2a-2d). More 
recently stage 0 has been added when the chest roentgenogram shows none of these 
abnormalities. The classification has prognostic value as originally described by Scadding with 
a 90% likelihood of resolution in 2 years with stage 1, compared to about 30% with stage 3.  
Although the radiologic staging does tend to correlate with physiologic impairment, its 
value in managing individual patients is limited (2). 
 
     
(a)  Stage I                                                             (b)  Stage II 
                
    (c)  Stage III                                                              (d)  Stage IV 
Fig. 2. Chest radiographs showing sarcoidosis stages I-IV. 
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Computed tomographic scans (CT scans) especially using high resolution technique 
(HRCT), provide much greater detail than routine chest radiographs. Common patterns in 
sarcoidosis include widespread pulmonary nodules, infiltrates with a bronchovascular and 
subpleural distribution (fig.3a), thickened intralobular septa, and as shown in figure 3b, 
architectural distortion, and conglomerate masses (10).  
 




Fig. 3. (a) CT scan showing bronchovascular distribution of pulmonary infiltrates in stage III 
sarcoidosis.      
Intrathoracic adenopathy is also more often detected on CT (11). It is unclear, however, that 
CT scanning adds critical diagnostic information beyond that of plain chest radiographs in 
the initial evaluation of most patients with suspected sarcoidosis. Whatever additional 
information is derived must be balanced against the added expense and radiation exposure 
associated with CT scans.  
Gallium-67 scanning may be of value in the initial diagnostic evaluation. Parotid and 
lacrimal gland uptake (positive Panda sign) plus bilateral hilar and right paratracheal lymph 
node uptake (positive Lambda sign) strongly support the diagnosis (11) (Figs 4a,b). Like CT 
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scans, the additional cost and radiation exposure with gallium scanning are not warranted 
in most cases.  Angiotensin-converting enzyme (ACE) is produced in epithelioid cells within 
sarcoid granulomas. Elevated levels of ACE were once felt to be diagnostic of sarcoidosis 
(12). More recent data indicate that ACE levels are neither sufficiently sensitive nor specific 
to confirm a diagnosis of sarcoidosis although they may have some value as supportive 
evidence for or against the diagnosis (2). 
 
                                  
 
                
(a)                                                                    (b) 
Fig. 4. (a) Gallium scan showing (a) Lamda sign; (b) Panda sign. 
5. Diagnosis without biopsy 
There are 4 circumstances where the diagnosis of sarcoidosis may be confidently made 
without biopsy because the combined clinical and radiographic findings are highly specific 
(2, 11). These situations are as follows: 1) asymptomatic patients with bilateral hilar 
adenopathy on chest x-ray, 2) Lofgren’s syndrome which consists of bilateral hilar 
adenopathy, erythema nodosum, and often fever and arthritis, 3) Heerfordt syndrome 
which includes uveitis, parotiditis and fever, and 4) when a gallium-67 scan shows Panda 
and Lambda signs as previously described. 
6. Invasive diagnostic modalities and appropriate biopsy sites 
Most patients with suspected sarcoidosis require histologic confirmation for diagnosis. Since 
sarcoidosis is a multi-system disorder, evidence of granulomatous inflammation in at least 2 
organs is required to distinguish it from granulomatous disorders of individual organs such 
as granulomatous hepatitis and idiopathic panuveitis (2, 11). However, biopsy confirmation 
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from one organ is deemed sufficient if compatible clinical, laboratory, or radiologic findings 
are consistent with the diagnosis in at least one additional organ and alternative diagnoses 
have been excluded (2, 11).  Positive biopsy material from more than one organ system may 
be necessary when sarcoidosis presents in an atypical fashion (11).   
The choice of biopsy site should be guided by what is least invasive and most likely to yield 
diagnostic material.  Enlarged peripheral lymph nodes, skin involvement, and conjunctival 
nodules permit minimally invasive procedures. The Kveim test developed more than 50 
years ago (13), involves a subcutaneous injection of material from a human spleen involved 
with sarcoidosis. A positive test is defined by the appearance of a nodular lesion at the site 
after 4-6 weeks which on biopsy shows non-caseating granulomas. The Kveim test has been 
reported to be fairly specific, but the sensitivity is low (11). It is not in general use because 
both sensitivity and specificity vary with the splenic material used, and it is not approved 
by the Food and Drug Administration in the United States (11).. 
Since over 90% of patients present with intra-thoracic involvement, bronchoscopy is often 
the diagnostic procedure of choice. Flexible fiberoptic bronchoscopy provides multiple 
options for obtaining diagnostic material. Lung parenchyma can be sampled by 
transbronchial lung biopsy (TBLB). Granulomas may be identified via endobronchial biopsy 
(EBB) in the central airways. Mediastinal and hilar lymph nodes may be accessed with 
transbronchial needle aspiration (TBNA). Bronchalveolar lavage (BAL) yields liquid 
material from one or more lung segments that can be helpful diagnostically. It also provides 
substrate for microbiologic studies to exclude conditions which figure strongly in the 
differential diagnosis, such as tuberculosis and fungal infections.  
The diagnostic yield of TBLB ranges from 60% to 97% depending on the radiographic stage 
of the disease and the number of biopsies performed (14).  In radiographic stage I where the 
pulmonary parenchyma appears normal on plain radiograph, the yield is approximately 
50% (15, 16). Even when the lungs do not show abnormalities on HRCT, TBLB may still be 
diagnostic (17).  The number of biopsies required to maximize diagnostic yield plateaus at 4-
5 specimens (18).  
Endobronchial involvement is frequent in sarcoidosis.  In the presence of abnormalities of 
the bronchial mucosa including nodularity, hypervascularity and bronchial stenosis, EBB 
has been reported to be diagnostic in over 90% of cases (19).  Even when the mucosa appears 
normal, a positive biopsy may be obtained in about 30% of cases (19, 20). Moreover, the 
addition of EBB to TBLB increases overall diagnostic yield (19, 20). EBB should probably be 
considered in all patients undergoing bronchoscopy for suspected sarcoidosis since it adds 
minimally in terms of risk and procedure time. 
Bronchoalveolar lavage (BAL) can be of value in the diagnosis of sarcoidosis. Analysis of 
BAL fluid typically shows a normal or modestly increased cell count, a lymphocyte 
predominance in over 90% of patients, a normal percentages of neutrophils and eosinophils, 
and absence of foamy alveolar macrophages and plasma cells (10, 21). These findings are 
helpful in distinguishing sarcoidosis from several conditions with similar clinical and 
radiologic features, specifically, extrinsic allergic alveolitis, nonspecific interstitial 
pneumonia, and idiopathic pulmonary fibrosis. Examination of lymphocyte populations 
(CD4/CD8 ratio) may also be diagnostically helpful. Several studies have shown that a 
CD4/CD8 ratio of greater than 3.5 has a specificity of 93-96%, although the sensitivity is low 
(53-59%) (22-25).In inactive sarcoidosis, the ratio is usually normal. In patients with only 
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extrathoracic manifestations, BAL may still show findings typical of sarcoidosis even when 
thoracic imaging studies are normal (26). 
Endobronchial ultrasound (EBUS) is a new approach to obtain histologic confirmation of 
intrathoracic sarcoidosis. Formerly, transbronchial needle aspiration (TBNA) using 
anatomical landmarks and fluoroscopy to guide the site of needle insertion in the airway 
was the standard bronchoscopic technique for sampling mediastinal lymph nodes in 
suspected sarcoidosis and other conditions particularly bronchogenic carcinoma. The ability 
to visualize lymph nodes via EBUS has resulted in diagnostic yields in sarcoidosis 
approaching 85% in experienced hands (27, 28). In one study, the diagnosis was confirmed 
in 96% of patients using EBUS compared to 73% using TBNA without EBUS despite the use 
of smaller gauge needles (19g for TBNA alone vs 22g with EBUS) (29).  Furthermore, EBUS 
has the added ability to biopsy smaller nodes not easily accessible by blind TBNA or 
mediastinoscopy.  Procedure times and amount of sedation needed tend to be modestly 
higher with EBUS compared to blind TBNA.  The frequency of complications is low for both 
techniques and roughly similar (29). Combining endoscopic (esophageal) ultrasound (EUS) 
with EBUS has the added advantage of accessing additional lymph node stations in the 
mediastinum and has proven to be an invaluable tool in lung cancer staging. In the 
evaluation of sarcoidosis it remains unclear if the combined modality (EBUS plus EUS) 
results in improved diagnostic yield (29).   
When less invasive modalities are inconclusive in suspected sarcoidosis, confirmation using 
one of several surgical options may be necessary. Mediastinoscopy remains the “gold 
standard” to evaluate abnormal mediastinal lymph nodes. For mediastinal lymph 
adenopathy of diverse etiologies, mediastinoscopy is diagnostic in 82-97% of reported cases 
(30).  The high yield reflects the generous volume of biopsy material obtainable with this 
technique. However, significant morbidity ranges from 1.4-2.3% (31).  Other disadvantages 
include higher cost compared to less invasive procedures, the need for general anesthesia, 
and the cosmetic effects of a neck scar.  Video-assisted thoracoscopic surgery (VATS) or 
open thoracotomy provide the ultimate approach for biopsy of lung parenchyma and/or 
mediastinal and hilar lymph nodes in sarcoidosis. 
7. Additional diagnostic modalities 
Occasionally, the clinical presentation suggests the diagnosis of sarcoidosis but no readily 
available biopsy site is identified, or only a single organ system is involved. Under such 
vexing clinical scenarios additional studies may be warranted to help identify occult sites of 
disease for diagnostic biopsy or to help identify the presence of granulomatous 
inflammation in relatively inaccessible organs (ie.. heart and brain). Traditionally gallium 
scanning was used in this regard, however newer modalities including F-18 
fluorodeoxyglucose positron emission tomography (PET) and gadolinium enhanced 
magnetic resonance imaging (MRI) may have improved diagnostic sensitivity (32).  FDG 
PET scanning has been shown to be sensitive for evaluating areas of active granulomatous 
inflammation in sarcoidosis. When interpreting PET scans caution is appropriate as positive 
scans can also be seen in patients with other granulomatous diseases, infections, and 
neoplasms.  It has recently been proposed that combining a more specific tracer L- (3-18F) – 
alpha – methytyrosine scan with an FDG PET scan can help differentiate neoplasm from 
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sarcoidosis (33).  PET scanning has also been shown to have a specific pattern in cardiac 
sarcoidosis.   
Like PET scanning, the use of MRI in suspected sarcoidosis has been shown to have value in 
the identification of occult disease especially cardiac and central nervous system 
involvement (34).  Recent studies suggest that PET scanning may be more sensitive than 
MRI for detection of cardiac sarcoidosis. However, MRI appears to have a higher specificity 
(35), and unlike PET, MRI does not expose patients to ionizing radiation.   
8. Conclusions 
The diagnostic approach in sarcoidosis can be relatively straight forward, but not 
infrequently it is arduous and complex. The multi-system nature of the condition, its 
protean manifestations, and unknown causation, all contribute to its elusive diagnostic 
nature. The routine clinical tools and diagnostic modalities discussed in this chapter provide 
an approach that will usually succeed. However, a degree of skepticism and ample 
consideration of alternative diagnoses are warranted. 
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